ARTICLES BY TYLER MENICHIELLO

  • Unlocking The Pharmacological Potential Of Antibodies
    8/20/2025

    Abalone Bio's CEO and co-founder, Richard Yu, Ph.D., explains the company's Functional Antibody Selection Technology (FAST) platform and its approach to developing a pipeline of G protein-coupled receptor (GPCR) mAbs.

Tyler Menichiello NL Headshot v3 Square

Tyler Menichiello

Tyler Menichiello is chief editor of Bioprocess Online, where he interviews biopharma executives and subject matter experts about the industry’s most pressing challenges. He aims to deliver actionable insights for biologics developers and manufacturers. Previously, he spent two years as a clinical research associate at the University of Pittsburgh Medical Center’s (UPMC) Hillman Cancer Center, working on clinical trials for hematological malignancies. He studied biology and journalism at Indiana University of Pennsylvania (IUP). You can connect with Tyler on LinkedIn.